Wee-1 kinase inhibitor AZD1775

DRUG2 trials

Sponsors

AstraZeneca

Conditions

Solid TumorsSolid Tumours

Phase 1

AZD1775 Continued Access Study to Assess Safety and Tolerability for Patients Enrolled in AZD1775 Clinical Pharmacology Studies

CompletedNCT03313557

AstraZenecaSolid Tumors

Start: 2017-10-27End: 2019-05-17Updated: 2019-06-24

Effects of AZD1775 on the PK Substrates for CYP3A, CYP2C19, CYP1A2 and on QT Interval in Patients With Advanced Cancer

CompletedNCT03333824

AstraZenecaSolid Tumours

Start: 2017-12-01End: 2019-01-22Updated: 2019-03-25

Related Papers

Phase I study to assess the effect of adavosertib (AZD1775) on the pharmacokinetics of substrates of CYP1A2, CYP2C19, and CYP3A in patients with advanced solid tumors.

2023-07-021 citations

Adavosertib (AZD1775) does not prolong the QTc interval in patients with advanced solid tumors: a phase I open-label study.

2023-06-27

Abstract 591: Adavosertib (AZD1775) does not prolong QT interval in patients with advanced solid tumors: A Phase I open-label study

Cancer Research2020-08-151 citations

Abstract 3035: Phase I study to assess the effect of adavosertib (AZD1775) on the pharmacokinetics of substrates of CYP1A2, CYP2C19 and CYP3A4 in patients with advanced solid tumors

Cancer Research2020-08-151 citations